About MedicaMetrix

MedicaMetrix, Inc. was founded in 2004 and has developed its first product, ProstaGlove™, for the quantitative measurement of prostate volume that will become the new “gold standard” for prostate exams and prostate cancer diagnosis.

Issue and Opportunity

Today PSA is the principal marker for prostate cancer screening and is used to screen males for prostate cancer beginning at age 50. Men with a blood serum PSA>4 ng/ml are referred for prostate biopsy. However, approximately 75% of prostate biopsies (at approximately $1,560/biopsy) are negative, i.e. patients do not have prostate cancer. With approximately 1.1 Million prostate biopsies performed annually, an estimated $1.4B is spent in the U.S. annually on prostate biopsies with negative results.

ProstaGlove^tm enables the measurement of prostate volume which can be used to calculate PSA Density ("PSAD") a much more effective marker for determining which men with elevated PSA should have a prostate biopsy.

Download Company Profile (PDF)

To view PDF Files, you must have Acrobat Reader. Download Adobe Acrobat